Market News & Trends
Catalent Biologics Expands Into ADCs Through Exclusive License
Catalent Pharma Solutions recently announced it has acquired an exclusive license to market Redwood Bioscience's proprietary SMARTag precision protein-chemical engineering technology for the development of…
Cyclica & Dalton Announce Drug Development Collaboration
Cyclica and Dalton recently announced a collaboration agreement to identify and develop new drug candidates applying advanced computational molecular design to medicinal chemistry and drug…
GSK & A*STAR to Develop New Medicines for Emerging Markets
GlaxoSmithKline (GSK) and A*STAR's Institute of Chemical and Engineering Sciences (ICES) have signed a 5-year strategic agreement to develop new evidence-based formulations (EBFs) specifically for…
Lipid Therapeutics Successfully Files US IND
Lipid Therapeutics recently announced it has successfully filed its first US IND for its lead product LT-02 and is now in a position to proceed…
Aragen Bioscience & Innovent Biologics Announce Collaboration for Biotherapeutic Product Development
Aragen Bioscience, Inc. and Innovent Biologics, Inc. have initiated a collaboration for the development of manufacturing cell lines for biotherapeutic product development. Under the terms…
Foster Expands Nano-Reinforced Polymer Product Range for Medical Devices
Foster Corporation now offers nano-reinforced composites for minimally invasive devices, such as catheters, with reinforcement loadings up to 30% by weight. Nano-reinforced compounds with high…
Hovione Announces a Co-Promotion & Collaboration Agreement
Hovione recently announced a co-promotion and collaboration agreement with Ligand to provide Hovione's customers efficient access to Captisol technology. Captisol, a chemically modified cyclodextrin, is…
Unilife Signs Long-Term Customization & Commercial Supply Agreement; $110-Million Potential
Unilife Corporation recently announced the signing of a Customization and Commercial Supply Agreement with a US pharmaceutical company for the EZMixTM dual-chamber syringe. Unilife will…
US Nanotechnology Drug Delivery Market Forecast to Grow Significantly Through 2016
Research activities in healthcare have changed significantly in recent years. There has been a paradigm shift away from blockbusters drugs to a more personalized medicine…
Vetter's New Commercial Filling Line Ready for cGMP Filling
Vetter recently announced that its new award-winning filling line at the company's Ravensburg Vetter South facility is fully validated and ready for cGMP filling, after…
Aastrom Biosciences Announces Strategic Change in R&D Programs
Aastrom Biosciences, Inc. recently announced a strategic change in its research and development programs to focus on the clinical development of its lead product, ixmyelocel-T,…
Biodel Completes Phase II Enrollment in Clinical Trial of Ultra-Rapid-Acting Insulin
Biodel Inc. recently announced the completion of patient enrollment in a Phase II clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of…
Foster Delivery Science Receives Grant to Develop Process for Oral Dose Drug Delivery
Foster Delivery Science recently announced it has been awarded a Manufacturer's Technical Assistance Program (MTAP) grant from the University of Connecticut for development of novel…
Medicyte Signs Development Agreement With Life Technologies
Medicyte recently announced it has signed a licensing agreement for the rights to use Lentiviral vector technology from Life Technologies to develop and market next-generation,…
RedHill Biopharma Submits NDA for Oral Thin Film Drug
RedHill Biopharma Ltd. recently announced the company and its co-development partner, IntelGenx Corp., have submitted a New Drug Application (NDA) to the USFDA seeking marketing…
VIVUS Announces $110-Million Synthetic Capped Royalty Financing
VIVUS, Inc. recently announced that it has entered into a $110-million non-equity financing with an investment fund managed by Pharmakon Advisors. Under the terms of…
OXiGENE Announces Patent Issuance for Novel Anticancer Class of Agents
OXiGENE, Inc. recently announced the US Patent and Trademark Office issued US Patent No. 8,397,859, covering certain benzosuberene-based compounds, including the analogues referred to as…
PerkinElmer Introduces Novel Non-Invasive Near-Infrared Imaging Agent
PerkinElmer recently introduced The GFR-Vivo 680 imaging agent, the first fluorescent agent that allows researchers to measure glomerular filtration rate (GFR) non-invasively, in vivo in…
Study Results for Two-Week Dosing Arm at Year 1
Primary Endpoint"¢ PLEGRIDY met the primary endpoint of reducing annualized relapse rate (ARR) at 1 year by 36% compared to placebo (p=0.0007). Secondary Endpoints"¢ PLEGRIDY…
Biogen's Injectable Drug Significantly Cuts Relapse Rate
Biogen Idec recently announced the positive, full first-year results from its 2-year pivotal Phase III ADVANCE study of PLEGRIDY (peginterferon beta-1a), the company's investigational candidate…
